01:42 , May 4, 2019 |  BioCentury  |  Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
20:12 , Apr 23, 2019 |  BC Extra  |  Politics & Policy

Biopharma battling drug price regulations in Massachusetts

The Massachusetts House of Representatives is set to vote this week on a bill that would regulate the prices of the highest-cost drugs purchased by the state’s MassHealth Medicaid program. Massachusetts biopharma companies are fighting...
18:10 , Apr 23, 2019 |  BioCentury  |  Finance

Accelerating innovations in Cambridge

As the Cambridge, U.K., life sciences start-up environment continues to flourish, Cambridge Innovation Capital’s Michael Anstey believes the city lacked a crucial element to foster start-ups’ growth: a “true U.S.-style accelerator” to provide capital, mentorship...
11:00 , Apr 18, 2019 |  BioCentury  |  Finance

Arranging Arrakis' syndicate

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become...
00:16 , Apr 6, 2019 |  BioCentury  |  Finance

Room to rally in 2Q

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled...
15:47 , Mar 28, 2019 |  BioCentury  |  Product Development

Contracting practices limiting U.S. biosimilars uptake

The U.S. biosimilars market lags Europe’s and won’t catch up until physicians understand and become comfortable with the concept of similarity, Sheila Frame, who heads up Sandoz’s North American biosimilars business, told BioCentury. To create...
14:14 , Mar 25, 2019 |  BioCentury  |  Emerging Company Profile

China Oncology Focus: funding combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking...
01:34 , Mar 23, 2019 |  BioCentury  |  Tools & Techniques

A frequentist and a Bayesian walk into a trial

In the stand-off between Bayesians and frequentists, the latter own the show for pivotal trials. But with non-profits leading the drive, Bayesians are poised to enter late-stage development via platform trials in cancer. The next...
21:06 , Feb 28, 2019 |  BC Innovations  |  Tools & Techniques

Synuclein PET project

As the Parkinson’s field starts to solve the problem of how to detect toxic α-synuclein in the brain, it’s closing in on imaging agents that could de-risk clinical trials. Phase I data expected this year...
13:54 , Feb 14, 2019 |  BioCentury  |  Finance

HKEX: where East meets West

Unfazed by the shaky start of the Hong Kong stock exchange’s new biotech chapter, HKEX CEO Charles Li thinks its position at the nexus of East and West will underpin its long-term success. With more...